

Best Practice Guidelines for Treatment of Lower Respiratory Infection in Long Term Care

Table 1. Primary and secondary findings are necessary to initiate antibiotics for bacterial pneumonia (PNA) or COPD exacerbation.

Clinical Findings					Clinical Response	
Primary		Secondary		Primary and secondary both present	Either Primary or Secondary absent	
Afebrile	Other comorbidities	New productive cough +	Either of the followingA. Respiratory rate > 25/minB. DeliriumEither of the following	Start antibiotics	Start active monitoring	
	COPD pre-existing	purulence +	A. Increased dyspneaB. Increased sputum volume		Re-evaluate next day	
		>1 of the following symptoms (include at least 1 Respiratory Specific)				
Fever	>100°F	Respiratory Specific- at least one	Respiratory Non-Specific		(do not start	
	<u>or</u>	-New or increase cough	-Delirium		antibiotics)	
	> 2.0°F above baseline <u>or</u>	-New or increase sputum	-Total WBC > 14,000* - Hypoxia (O2 sats < 90%)* -Pleuritic chest pain			
	2 X >99°F		-Respiratory rate > 25 breaths/min -Consolidation (on exam)	(Tables 2 & 3)	(Table 2)	
	High (>102F)	Respiratory Rate >25 and/or New Productive Cough		Consider ED		

* Secondary findings *italicized* may be documented/obtained by ordering these tests during active monitoring if resident initially does not meet criteria to start antibiotics

** Consider ordering chest X-ray and CBC with differential for febrile residents with cough and any of these criteria (HR >100, worsening mental status, or rigors) Antibiotics should not be used for up to 24 h after large-volume aspiration in those without COPD but with temp ≤38.9°C (102 °F) and non-productive cough



Best Practice Guidelines for Treatment of Lower Respiratory Infection in Long Term Care

TABLE 2. CLINICAL RESPONSE DETAILS

Start Antibiotics: Primary & secondary findings both present

- Test COVID PCR (+ isolation) if still active
- IF SEASONAL, √ RSV/INFLUENZA TESTING
- Choose antibiotic (Table 3)
- Diagnostics only if
 - If community/hospital legionella problem test urine Legionella
 - If not improving consider CXR, pulse oximetry, CBC

Start Active Monitoring: Either Primary or Secondary findings are absent

- Do not start antibiotics
- Consider COVID PCR test if still active monitoring
- If seasonal, consider V RSV/influenza testing
- If concerned or not improved **V CBC +/- CXR**
- Re-evaluate signs and symptoms every 24 hours.
 - If not improved, consider
 - upper respiratory infection (URI) (if productive cough is not noted)
 - non-infectious causes of pulmonary infiltrate, other infection source.

* In patients where suspicion of Legionella is low, and the burden/risks of sputum or urine acquisition is high, testing not justified. Urinary catheterization, induced sputum production, or nasotracheal suctioning are only necessary in patients or residents when suspicion of Legionella is high and require proper consent.

2019 American Thoracic Society/IDSA guidelines: (1) suggest Legionella antigen testing in cases where a known outbreak is occurring or severe disease in hospitalized patients; (2) adults with CAP when influenza viruses are circulating in the community test for influenza with a rapid molecular assay.



Mild	-Moderate				
	Scenario	Antibiotic to Start	Dosing and Duration (5 days)*	Considerations	
		Cefpodoxime	200 mg PO BID X 5 days	Safe in mild PCN allergy	
				Q 24 hrs if CrCL <30; or post HD X 3	
1 st	Moderate illness, able to			Alternative cefuroxime 500 mg PO BID	
line	take oral medication**				
		Amoxicillin/	500 mg/125 mg TID X 5 days	Equivalent to 875/125 mg BID	
		clavulanate			
	Severe contraindications to	Levofloxacin	750 mg PO Q 24 X 5 days OR	Pose a higher risk for C. difficile infection	
2 nd	1 st line		if CrCL<20 or ESRD, 750 x 1	Caution with anti-arrhythmic medications and	
line			dose, then 500 mg Q 48 hours	prolonged QTc. Mild PCN allergy not an indication	
			X 2 doses	for quinolones	
Speci	ial circumstances				
	Unable to take oral meds	Ceftriaxone IM/IV		Reserve IM for severe illness but reluctant to	
	Deterioration on oral	Ceftriaxone IM/IV	1000 mg IM Q 24 hours X 5	evaluate in ED/Hospital	
2 nd	agents, severe illness	AND			
line		Doxycycline OR	100 mg BID X 5 days	No renal adjustment needed	
		Azithromycin	500 mg X 3 days		
	Risk for Pseudomonas***	Levofloxacin	As above		
		monotherapy			
	Risk MRSA***	Doxy + 1 st line	100 mg BID X 5 days + 1 st line	Add doxy to first line agents.	
	Risk of or suspect aspiration	Use either 1 st line	Duration should be	Add anaerobic coverage only if abscess or	
			maintained at 5 days	empyema suspected: then amox/clavulanate, or ceftriaxone/metronidazole	

* Duration is 5 days. Only extend to 7 if signs/symptoms not improved at day 5 (i.e., still fever, use of supplemental O2, unstable vital signs.

We recommend B-lactam monotherapy. 2019 ATS/IDSA guidelines recommend combination therapy (b-lactam/macrolide) for outpatients with co-morbidities, but for nursing home residents without typical community-exposure to atypical organisms, min role for combination therapy, but not contraindicated. **Co-morbidities include chronic heart, lung, liver, renal disease; diabetes, alcoholism, malignancy, asplenia.

*** for MRSA = history of clinical culture with MRSA (sputum, wound, nasal) in past year; for Pseudomonas = history of + PSA in Sputum in past year or bronchiectasis/FEV1<35%. If NOT transferring to ED to get new sputum culture, use levofloxacin (pseudomonas) or doxy + 1st line agent (for MRSA). **IF able** to order sputum microbiology, stop additional coverage if no Pseudomonas or MRSA recovered.